19 relations: Almorexant, EMPA (drug), Filorexant, Fusion protein, G protein–coupled receptor, Gene, Hypocretin (orexin) receptor 1, Lemborexant, Mary Ann Liebert, Inc., Nemorexant, Orexin, Orexin receptor, Orexin-A, Protein, Receptor antagonist, SB-649868, Seltorexant, Suvorexant, TCS-OX2-29.
Almorexant (INN, codenamed ACT-078573) is an orexin antagonist, functioning as a competitive receptor antagonist of the OX1 and OX2 orexin receptors, which was being developed by the pharmaceutical companies Actelion and GSK for the treatment of insomnia.
EMPA is a selective antagonist of the OX2 receptor, with 900-fold selectivity in binding for OX2 over OX1.
Filorexant (INN, USAN) (code name MK-6096) is an orexin antagonist which is or was under development by Merck for the treatment of insomnia.
Fusion proteins or chimeric (\kī-ˈmir-ik) proteins (literally, made of parts from different sources) are proteins created through the joining of two or more genes that originally coded for separate proteins.
G protein–coupled receptors (GPCRs), also known as seven-(pass)-transmembrane domain receptors, 7TM receptors, heptahelical receptors, serpentine receptor, and G protein–linked receptors (GPLR), constitute a large protein family of receptors that detect molecules outside the cell and activate internal signal transduction pathways and, ultimately, cellular responses.
In biology, a gene is a sequence of DNA or RNA that codes for a molecule that has a function.
Orexin receptor type 1 (Ox1R or OX1), also known as hypocretin receptor type 1 (HcrtR1), is a protein that in humans is encoded by the HCRTR1 gene.
Lemborexant (code name E-2006) is a dual antagonist of the orexin OX1 and OX2 receptors which is under development by Eisai for the treatment of insomnia.
Mary Ann Liebert, Inc. is a privately held independent publishing company founded by its president, Mary Ann Liebert, in 1980.
Nemorexant (developmental code name ACT-541468) is a dual orexin receptor antagonist (DORA) which was originated by Actelion Pharmaceuticals and is under development by Idorsia Pharmaceuticals for the treatment of insomnia.
Orexin, also known as hypocretin, is a neuropeptide that regulates arousal, wakefulness, and appetite.
The orexin receptor (also referred to as the hypocretin receptor) is a G-protein-coupled receptor that binds the neuropeptide orexin.
Orexin-A, also known as hypocretin-1, is a naturally occurring neuropeptide and orexin isoform.
Proteins are large biomolecules, or macromolecules, consisting of one or more long chains of amino acid residues.
A receptor antagonist is a type of receptor ligand or drug that blocks or dampens a biological response by binding to and blocking a receptor rather than activating it like an agonist.
SB-649868 is a dual orexin receptor antagonist in development by GlaxoSmithKline.
Seltorexant (former developmental code names MIN-202, JNJ-42847922, JNJ-922) is a selective, small-molecule antagonist of the OX2 receptor that is under development by Minerva Neurosciences and Johnson & Johnson's Janssen Pharmaceutica for the treatment of insomnia and major depressive disorder (MDD).
Suvorexant, sold under the trade name Belsomra, is a medication for the treatment of insomnia.
TCS-OX2-29 is an orexin antagonist.